Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Literature DB >> 24806343

Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Abstract

Alzheimer's disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass spectrometry (MS)-based proteomics studies on AD and discuss thoroughly the methods to identify candidate biomarkers in cerebrospinal fluid (CSF) and blood. This review will also discuss the potential research areas on biomarkers.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2014 PMID： 24806343 PMCID： PMC4057708 DOI： 10.3390/ijms15057865

Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923

132 in total

1. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue.

Authors: M Herrmann; A D Ebert; I Galazky; M T Wunderlich; W S Kunz; C Huth
Journal: Stroke Date: 2000-03 Impact factor: 7.914

Review 2. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors: Nader Rifai; Michael A Gillette; Steven A Carr
Journal: Nat Biotechnol Date: 2006-08 Impact factor: 54.908

3. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.

Authors: Madhav Thambisetty; Yang An; Anna Kinsey; Deepthi Koka; Muzamil Saleem; Andreas Güntert; Michael Kraut; Luigi Ferrucci; Christos Davatzikos; Simon Lovestone; Susan M Resnick
Journal: Neuroimage Date: 2011-07-28 Impact factor: 6.556

4. Bring on the biomarkers.

Authors: George Poste
Journal: Nature Date: 2011-01-13 Impact factor: 49.962

Review 5. Protein analysis by shotgun/bottom-up proteomics.

Authors: Yaoyang Zhang; Bryan R Fonslow; Bing Shan; Moon-Chang Baek; John R Yates
Journal: Chem Rev Date: 2013-02-26 Impact factor: 60.622

Review 6. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.

Authors: David Prvulovic; Harald Hampel
Journal: Clin Chem Lab Med Date: 2011-02-23 Impact factor: 3.694

7. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.

Authors: E R Peskind; W S Griffin; K T Akama; M A Raskind; L J Van Eldik
Journal: Neurochem Int Date: 2001 Nov-Dec Impact factor: 3.921

Review 8. β-Secretase: its biology as a therapeutic target in diseases.

Authors: Haibo Wang; Rena Li; Yong Shen
Journal: Trends Pharmacol Sci Date: 2013-02-27 Impact factor: 14.819

9. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

Authors: A K Wallin; O Hansson; K Blennow; E Londos; L Minthon
Journal: Int J Geriatr Psychiatry Date: 2009-06 Impact factor: 3.485

10. NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers.

Authors: Kiyoshi Fukuhara; Akiko Ohno; Yosuke Ota; Yuya Senoo; Keiko Maekawa; Haruhiro Okuda; Masaaki Kurihara; Alato Okuno; Shumpei Niida; Yoshiro Saito; Osamu Takikawa
Journal: J Clin Biochem Nutr Date: 2013-03-01 Impact factor: 3.114

11 in total

1. CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Authors: Astrid Guldbrandsen; Yehia Farag; Ann Cathrine Kroksveen; Eystein Oveland; Ragnhild R Lereim; Jill A Opsahl; Kjell-Morten Myhr; Frode S Berven; Harald Barsnes
Journal: Mol Cell Proteomics Date: 2016-11-27 Impact factor: 5.911

2. Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men.

Authors: Satoru Kira; Takahiko Mitsui; Tatsuya Miyamoto; Tatsuya Ihara; Hiroshi Nakagomi; Yuka Hashimoto; Hajime Takamatsu; Masayuki Tanahashi; Masahiro Takeda; Norifumi Sawada; Karl-Erik Andersson; Masayuki Takeda
Journal: World J Urol Date: 2019-01-23 Impact factor: 4.226

Review 3. Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors: Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal: Mol Cell Proteomics Date: 2015-12-11 Impact factor: 5.911

4. Urinary metabolites identified using metabolomic analysis as potential biomarkers of nocturia in elderly men.

Authors: Satoru Kira; Takahiko Mitsui; Tatsuya Miyamoto; Tatsuya Ihara; Hiroshi Nakagomi; Yuka Hashimoto; Hajime Takamatsu; Masayuki Tanahashi; Masahiro Takeda; Sachiko Tsuchiya; Norifumi Sawada; Masayuki Takeda
Journal: World J Urol Date: 2019-12-03 Impact factor: 4.226

Review 5. Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Authors: Sunil S Adav; Siu Kwan Sze
Journal: Mol Brain Date: 2016-11-03 Impact factor: 4.041

Review 6. Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease.

Authors: K Rajasekhar; Thimmaiah Govindaraju
Journal: RSC Adv Date: 2018-06-29 Impact factor: 4.036